http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Pharmacosmos Group to Acquire G1 Therapeutics
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
-
G1 Therapeutics Added to the Russell 2000® and 3000® Indexes
-
G1 Therapeutics (GTHX) Provides Update on Phase 3 PRESERVE 2 Trial
-
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
G1 Therapeutics (GTHX) Reports Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib with TROP2 Antibody-Drug Conjugate
-
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
-
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
-
G1 Therapeutics to Participate in TD Cowen’s 5th Annual Oncology Innovation Summit
-
G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
-
G1 Therapeutics (GTHX) and Pepper Bio Enter License Agreement for Lerociclib
-
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
-
G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
-
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
-
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
-
G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024
-
G1 Therapeutics (GTHX) to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis
-
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
-
G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
-
G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
G1 Therapeutics (GTHX) Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
-
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium
-
G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights
-
G1 Therapeutics (GTHX) Reports Data Showing Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with ES-SCLC
-
Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
-
G1 Therapeutics' (GTHX) COSELA Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology
-
G1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO)
-
G1 Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 1, 2023
-
G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium
-
G1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights
-
G1 Therapeutics to Participate in Two August Investor Conferences
-
New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
-
G1 Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 2, 2023
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
G1 Therapeutics Announces Appointment of Monica Thomas as General Counsel
-
New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer
